Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-01
DOI
10.1038/s41598-017-03153-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic and predictive markers in pancreatic adenocarcinoma
- (2016) Nha Le et al. DIGESTIVE AND LIVER DISEASE
- Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer
- (2016) Hiroshi Imaoka et al. PANCREAS
- The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer
- (2016) Mengwan Wu et al. TUMOR BIOLOGY
- The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection
- (2016) Koichiro Haruki et al. WORLD JOURNAL OF SURGERY
- Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer
- (2015) Mitsuru Ishizuka et al. ANNALS OF SURGICAL ONCOLOGY
- A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
- (2015) Xiao-li Wei et al. BMC CANCER
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The systemic inflammation-based Glasgow Prognostic Score as a prognostic factor in patients with acute heart failure
- (2015) Shigeto Namiuchi et al. Journal of Cardiovascular Medicine
- Inflammation and cancer: advances and new agents
- (2015) Shanthini M. Crusz et al. Nature Reviews Clinical Oncology
- Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer
- (2015) Takahiro Kishi et al. PANCREATOLOGY
- Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer
- (2015) Q. Qi et al. PANCREATOLOGY
- Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer
- (2015) Xuechao Liu et al. Translational Oncology
- Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
- (2015) Ting Zhou et al. Scientific Reports
- Precedent Fluctuation of Serum hs-CRP to Albumin Ratios and Mortality Risk of Clinically Stable Hemodialysis Patients
- (2015) Jyh-Chang Hwang et al. PLoS One
- A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma
- (2015) Xiao-Ling Xu et al. PLoS One
- C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review
- (2015) Shiva Shrotriya et al. PLoS One
- The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma
- (2014) Akiyoshi Kinoshita et al. ANNALS OF SURGICAL ONCOLOGY
- Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients
- (2014) Peng Xue et al. Cancer Medicine
- Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients
- (2013) J Szkandera et al. BRITISH JOURNAL OF CANCER
- Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
- (2013) Michael Haas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
- (2012) Peter J. Hosein et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma
- (2012) Marco La Torre et al. ANNALS OF SURGICAL ONCOLOGY
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
- (2012) Jan Budczies et al. PLoS One
- An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
- (2011) M J Proctor et al. BRITISH JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
- (2010) Michael Haas et al. TUMOR BIOLOGY
- Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas
- (2009) J.K. Pine et al. EJSO
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started